This is a demo store. No orders will be fulfilled.

HLY78 - 10mM in DMSO, high purity , CAS No.854847-61-3(DMSO)

    Grade & Purity:
  • 10mM in DMSO
In stock
Item Number
H656768
Grouped product items
SKU Size
Availability
Price Qty
H656768-1ml
1ml
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$110.90

Basic Description

Specifications & Purity 10mM in DMSO
Biochemical and Physiological Mechanisms HLY78, a Lycorine ( HY-N0288 ) derivative, is a potent activator of the Wnt/β-catenin signaling pathway. HLY78 targets the DIX domain of Axin and promotes the Axin-LRP6 (lipoprotein receptor-related protein 6) association, thus promoting LRP6 phosphorylat
Storage Temp Store at -80°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Product Description

HLY78, a Lycorine derivative, is a potent activator of the Wnt/β-catenin signaling pathway. HLY78 targets the DIX domain of Axin and promotes the Axin-LRP6 (lipoprotein receptor-related protein 6) association, thus promoting LRP6 phosphorylation and Wnt signal transduction. HLY78 can be used for subarachnoid hemorrhage (SAH) research

In Vitro

HLY78 inhibits apoptosis in tumor cells and embryonic cells caused by carbon ion radiation through activation of the Wnt/β-catenin pathway. HLY78 (20 μM, 0-48 h) significantly increases the colony formation ability by 2.78-fold and 2.88-fold for HGC-27 and AGS cells compared with the controls. HLY78 (20 μM, 0-48 h) elevates the migration ability of HGC-27 and AGS cells. HLY78 significantly increases TNKS expression, which is ameliorated by Dihydroartemisinin . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

HLY78 (0-1.8 mg/kg, Intranasal injection, once) attenuates neuronal apoptosis and improves neurological deficits through the LRP6/GSK3β/β-catenin signaling pathway after SAH (subarachnoid hemorrhage) in rats. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Adult male Sprague-Dawley rats (280-310 g, n=9/group, SAH model)Dosage: 0, 0.2, 0.6, and 1.8 mg/kg Administration: Intranasal injection, once, at 1 h post-SAH (subarachnoid hemorrhage) Result: Significantly attenuated the short-term and long-term neurobehavioral deficits, as well as the neuronal apoptosis after SAH at 0.6 mg/kg. Successfully delivered into the brain via intranasal administration at 0.6 mg/kg and was sufficient to significantly increase the phosphorylation of LRP6. Reversed the changes of the Bcl-2, Bax, and cleaved caspase 3 levels.

IC50& Target:Wnt/β-catenin

Names and Identifiers

Smiles CCC1=C2C(=CC=C1)C3=CC4=C(C=C3CN2C)OCO4
Molecular Weight 267.32

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.